At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer.

We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

We believe our proprietary Fast-Clear™ linker technology is a safer approach to targeted radiopharmaceuticals. Fast-Clear™ represents a revolutionary step towards developing safe and effective new radiotherapeutics as the standard of care for the treatment of multiple tumor types.

We believe this evolution of radiopharmaceuticals holds great promise to improve the lives of patients with cancer.